CJC-1295 (without DAC) vs HGH
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both CJC-1295 (without DAC) and HGH can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
CJC-1295 (without DAC) HGH
Weight 3,367.97 Da 22,124 Da
Half-life 30 minutes - 2 hours 3-4 hours (SC), 20-30 minutes (IV)
Chain 30 amino acids 191 amino acids
Type GHRH analog Single-chain polypeptide with two disulfide bridges
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Research Evidence
CJC-1295 (without DAC) HGH
Status Well Studied FDA Approved
References 5 studies 4 studies
Latest November 2024 2024
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.